verified SJR 1,071 · Q1 • database Scopus / SJR & Web of Science indexed

United States · John Wiley and Sons Inc

workspace_premium Q1 — Oncology lock_open Open Access

Prostate

Prostate is a journal indexed in SJR in Oncology and Urology with an H index of 138. It has a price of 3083 €. It has an SJR impact factor of 1,071 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,071.

Prostate focuses its scope in these topics and keywords: prostate, cancer, cell, expression, prostatic, rat, risk, human, prostasomes, model, ...

ISSN: 0270-4137

Publisher: John Wiley and Sons Inc

Category: Oncology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,071 Q1

H-index 138

Acceptance rate pie_chart

23% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

3.083 € Open Access

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,071

H-index

138

Docs (year)

158

Docs 3y

487

Total refs

5924

Cites 3y

1308

Citable 3y

470

Cites/Doc 2y

2.51

Ref/Doc

37.49

Immediate OA

3083 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Application of serum PSA to identify acute bacterial prostatitis in patients with fever of unknown origin or symptoms of acute pyelonephritis

Where are the prostate cancer genes??A summary of eight genome wide searches

Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening population

Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia

Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines

Cell specific expression of CD10/neutral endopeptidase 24.11 gene in human prostatic tissue and cells

Can color doppler predict the uniformity of HIFU-induced prostate tissue destruction?

Ca2+ currents in smooth muscle cells isolated from human prostate

Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells

Bone extracellular matrix induces homeobox proteins independent of androgens: Possible mechanism for androgen-independent growth in human prostate cancer cells

Benign prostatic hyperplasia: A review of its histogenesis and natural history

Benign prostatic hyperplasia morbidity and mortality among immigrants in Australia and Canada

SHOW MORE ARTICLES

Association of prostate cancer risk and aggressiveness to androgen pathway genes:SRD5A2,CYP17, and theAR

1?,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway

Apoptotic impact of ?1-blockers on prostate cancer growth: A myth or an inviting reality?

Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models

Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC

Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER¬Æ microspheres) and radiation

Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients

Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy

Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer

Adenovirus-mediated expression of a soluble fibroblast growth factor receptor inhibits in vitro growth of prostate DU145 cells

A role for surfactant protein D in innate immunity of the human prostate

A Prospective longitudinal study comparing the impact of external radiation therapy with radical prostatectomy on health related quality of life (HRQOL) in prostate cancer patients

FAQs

Prostate has an SJR of 1,071 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 3083 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Prostate is 23%.

Prostate

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Prostate?

What is the APC / publication cost?

What is the acceptance rate?